前頭側頭障害治療薬の世界市場-2022-2029

市場力学

前頭側頭障害治療の世界市場の成長は、認知症やその他の前頭側頭障害の有病率の上昇、医薬品開発助成金の増加、政府および非政府組織による資金提供などが、市場成長を促進する主な要因となっています。

技術的進歩の高まりは、予測期間中に世界の前頭側頭障害治療市場を牽引すると予想されます。

世界保健機関（WHO）によると、約5,000万人が認知症であり、毎年約1,000万人が新たに発症していることから、業界の成長を後押しすると予想されます。

前頭側頭型認知症は、認知症患者全体の2～5%を占めています。認知症の有病率は、2050年までに3倍になると予測されています。認知症統計機構によると、認知症患者数は2018年の5,000万人から2050年には1億5,200万人と204%増加すると予測されています。認知症患者数の増加は、前頭側頭型認知症の症例をさらに増加させ、前頭側頭型障害治療薬や薬剤の需要をさらに高めると予想されます。

また、対象疾患の治療法を見つけるための研究活動に対する政府の支援や資金提供の高まりは、市場の成長を促進すると予想されます。国立衛生研究所（NIH）、アルツハイマー病協会、国立加齢研究所など、複数の組織が新薬の開発に携わっています。2019年、NIHはアルツハイマー病関連認知症（ADRD）の研究プロジェクトに約3億8700万米ドルを支出しました。これらの取り組みにより、予測期間中の市場成長が促進されることが期待されます。

新興国における対象疾患に対する認識不足が市場成長の妨げとなる可能性

前頭側頭型認知症は、認知症治療薬として世界的に広く認知されていますが、適切な診断の欠如やアルツハイマー型認知症と誤解される可能性が高いことが、市場の成長を抑制しています。また、貧弱な治療レジメン、新しい治療法の欠如も前頭側頭障害治療市場の成長を制限しています。

産業分析

前頭側頭障害治療の世界市場は、ポーターのファイブフォース分析、サプライチェーン分析、規制分析、価格分析などの様々な産業要因、アンメットニーズに基づいて、市場の詳細な分析を提供します。

セグメンテーション分析

抗うつ薬セグメントは予測期間（2022-2029年）に最も速いCAGRで成長すると予測される

薬物クラスに基づき、世界の前頭側頭障害治療市場は、抗精神病薬、認知機能改善薬、CNS刺激薬、抗うつ薬、その他に区分されます。これらのうち、抗うつ薬は予測期間中に有利な機会を示すと予想されます。抗うつ剤は主に、うつ病性障害や、その他、気分変調症、強迫性障害（OCD）、不安障害、神経障害性疼痛、摂食障害、慢性疼痛などの症状の治療に使用されます。その他、数種類の抗うつ剤が、患者の健康を効果的に管理するために医師によって広く処方されています。また、（SSRI）選択的セロトニン再取り込み阻害剤は、前頭側頭疾患の治療に有益であることが証明されています。

2018年10月、Lundbeck社はインドで大うつ病性障害の治療に使用されるBrintellix錠剤を発売しました。さらに、2019年4月、Lupinは抗うつ剤Fluoxetine錠をアメリカ市場で発売しました。この錠剤は、大うつ病性障害、強迫性障害の治療薬として適応があります。このように、患者数の増加や最近の製品上市により、市場は予測期間中に世界中で高い成長を遂げると予想されます。

当レポートでは、世界の前頭側頭障害治療市場について、約40以上の市場データ表、45以上の図表、180ページにわたる情報を提供しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• 薬効分類別市場内訳
• 適応症別市場内訳
• 流通チャネル別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 前頭側頭型障害の有病率の上昇
    • 政府・非政府組織別資金提供の増加
  • Restraints
    • 高い治療費
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• パイプライン分析
• サプライチェーン分析
• 価格設定分析
• 法規制分析
• アンメットニーズ
• COVID-19影響度分析

第6章 薬物クラス別

• 認知機能改善剤
• 抗精神病薬
  • アリピプラゾール
  • パリペリドン
  • オランゼピン
  • リスペリドン
  • クエチアピン
  • ジプラシドン
• 抗うつ剤
  • ブプロピオン
  • フルボキサミン
  • シタロプラム
  • フルオキセチン
  • ミトラゼピン
  • パロキセチン
  • セルトラリン
• 中枢神経系刺激薬
• その他

第7章 効能・効果別

• 行動変容型前頭側頭型認知症（BFTD）（BFTD）
• 原発性進行性失語症（PPA）
  • 意味性PPA
  • アグラマティックPPA
  • ロゴペインティックPPA
• 運動機能低下
  • 大脳皮質基底症候群（CBS）
  • 進行性核上性麻痺（PSP）

第8章 流通チャネル別

• 病院内薬局
• 小売薬局
• オンライン薬局
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 競合シナリオ
• 市況ポジショニング／シェア分析
• M&A（合併・買収）分析

第11章 企業プロファイル

• Apotex Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Johnson & Johnson
• Auro Pharma
• Pfizer Inc.
• Teva Pharmaceuticals USA, Inc.
• AstraZeneca plc.
• Mylan N.V.
• Sanofi S.A.
• Valeant Pharmaceutical International
• Eli Lilly and Company（LIST NOT EXHAUSTIVE）

第12章 DataM

Market Overview

The Frontotemporal Disorders Treatment Market size was valued at USD 721.4 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 6.50% over the forecast period 2022 to 2029.

Frontotemporal disorder, commonly known as Pick disease, is a form of dementia that is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia that causes behavior and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain.

The Frontotemporal Disorders Treatment Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Frontotemporal Disorders Treatment Market segmentation by drug class, procedure, and Distribution Channel. It also provides market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Frontotemporal Disorders Treatment Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global frontotemporal disorders treatment market growth is driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants, and funding by the government as well as non-government organizations are the key factors driving the market growth.

The rising technological advancements, is expected to drive the global frontotemporal disorders treatment market during the forecast period;

As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth.

Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia is projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.

Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). These initiatives are expected to boost market growth over the forecast period.

Lack of awareness towards the target disease in a developing country are likely to hinder the market growth

However, lack of proper diagnosis and higher chances of misunderstanding with Alzheimer's disease is restraining the growth of the frontotemporal dementia treatment market. Additionally poor treatment regimens lack of novel therapies is also limiting the Frontotemporal dementia treatment market growth.

Industry Analysis

The global frontotemporal disorders treatment market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis etc, unmet needs.

Segmentation Analysis

The antidepressants segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the global frontotemporal disorders treatment market is segmented into antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to show a lucrative opportunity over the forecast period. Antidepressant drugs are mainly used for the treatment of depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Several other types of antidepressants are widely prescribed by physicians to manage patient health effectively. Also, (SSRIs) selective serotonin reuptake inhibitors prove beneficial for the treatment of frontotemporal disorders.

In October 2018, Lundbeck launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Furthermore, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, and obsessive-compulsive disorder. Thus, owing to the rising patient pool and recent product launches, the market is expected to witness high growth across the globe over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global frontotemporal disorders treatment market

North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, the rising prevalence of frontotemporal disorders in this region is driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications.

In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.

Competitive Landscape

The global frontotemporal disorders treatment market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Apotex Inc., Auro Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca plc., Mylan N.V., Sanofi S.A., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the frontotemporal disorders treatment market globally. For instance, on June 15th, 2020, ACADIA Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: ZFP-TFs to down-regulate the expression of tau, a protein associated with Alzheimer's disease and frontotemporal dementia (FTD).

The global frontotemporal disorders treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Drug Class
• 3.2. Market snippet by Indication
• 3.3. Market snippet by Distribution Channel
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Frontotemporal Disorders
    • 4.1.1.2. Increasing Funding by Government & Non-Government Organizations
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. High Cost of treatment
    • 4.1.2.2. XX
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pipeline Analysis
• 5.4. Supply Chain Analysis
• 5.5. Pricing Analysis
• 5.6. Regulatory Analysis
• 5.7. Unmet Needs
• 5.8. COVID-19 Impact Analysis

6. By Drug Class

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
• 6.3. Market Attractiveness Index, By Drug Class Segment
  • 6.3.1. Cognitive Enhancers*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3.2. Antipsychotics
    • 6.3.2.1. Aripiprazole
    • 6.3.2.2. Paliperidone
    • 6.3.2.3. Olanzepine
    • 6.3.2.4. Risperidone
    • 6.3.2.5. Quetiapine
    • 6.3.2.6. Ziprasidone
  • 6.3.3. Antidepressants
    • 6.3.3.1. Bupropion
    • 6.3.3.2. Fluvoxamine
    • 6.3.3.3. Citalopram
    • 6.3.3.4. Fluoxetine
    • 6.3.3.5. Mitrazepine
    • 6.3.3.6. Paroxetine
    • 6.3.3.7. Sertraline
  • 6.3.4. CNS stimulants
  • 6.3.5. Others

7. By Indication

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
• 7.3. Market Attractiveness Index, By Indication Segment
  • 7.3.1. Behaviour Variants Frontotemporal Dementia. (BFTD)*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Primary Progressive Aphasia (PPA)
    • 7.3.2.1. Semantic PPA
    • 7.3.2.2. Agrammatic PPA
    • 7.3.2.3. Logopenic PPA
  • 7.3.3. Motor Decline
    • 7.3.3.1. Corticobasal syndrome (CBS)
    • 7.3.3.2. Progressive supranuclear palsy (PSP)

8. By Distribution Channel

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
• 8.3. Market Attractiveness Index, By Distribution Channel Segment
  • 8.3.1. Hospital Pharmacies*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
  • 8.3.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. The U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. Australia
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. The Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Apotex Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Johnson & Johnson
• 11.3. Auro Pharma
• 11.4. Pfizer Inc.
• 11.5. Teva Pharmaceuticals USA, Inc.
• 11.6. AstraZeneca plc.
• 11.7. Mylan N.V.
• 11.8. Sanofi S.A.
• 11.9. Valeant Pharmaceutical International
• 11.10. Eli Lilly and Company (LIST NOT EXHAUSTIVE)

12. DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us